Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
As previously disclosed, on June 6, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools” or the “Company”), entered into an Agreement and Plan of
Merger and Reorganization (the “Merger Agreement”) by and among the Company, Treeline Biosciences, Inc., a Delaware corporation (“Treeline”), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger
Sub”). Pursuant to the Merger Agreement, on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Treeline (the “Merger”), with Treeline surviving the Merger as a wholly owned subsidiary of the Company.
In connection with the Merger and related stockholder vote, the Company filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on
Form S-4 (File No. 333-297560), as amended (the “Registration Statement”), which was declared effective by the SEC on October 21, 2026. The Registration Statement includes a proxy statement/prospectus with respect to the special meeting of the
Company’s stockholders scheduled to be held on November 19, 2026 (the “Special Meeting”) in connection with the Merger. The definitive proxy statement/prospectus was filed with the SEC on October 21, 2026 (the “Definitive Proxy
Statement/Prospectus”).
Certain Litigation
In connection with the Merger, between July 27, 2026 and November 9, 2026, the Company received 15 demand letters, including one demand made pursuant to Section 220 of
the Delaware General Corporation Law seeking certain books and records of the Company, from purported stockholders of the Company (the “Demand Letters”). The Demand Letters generally allege that the Registration Statement and/or the Definitive
Proxy Statement/Prospectus omits certain material information and seek additional disclosures.
In addition, on October 29, 2026 and October 30, 2026, purported stockholders of the Company filed two complaints in the Supreme Court of the State of New York, County
of New York, captioned Carroll v. Standard BioTools Inc., et al., Index No. 656182/2026, and Miller v. Standard BioTools Inc., et al., Index No. 656185/2026,
respectively (together, the “Complaints”). The Complaints name as defendants the Company and its directors and generally allege that the Definitive Proxy Statement/Prospectus omits certain material information.
The Company cannot predict the outcome of the Demand Letters, the Complaints or any potential litigation. The Company intends to vigorously defend against the Demand
Letters, the Complaints and any subsequently filed complaints or similar actions that may be filed. It is possible that additional demand letters and/or complaints may be received arising out of the Merger between the date of this Current Report on
Form 8-K and consummation of the Merger. Absent new or significantly different allegations, the Company will not necessarily disclose such additional filings or demand letters.
Although the Company believes that the disclosures set forth in the Definitive Proxy Statement/Prospectus comply fully with all applicable law and that no further
disclosure is required or necessary under applicable laws, and denies the allegations in the Demand Letters and the Complaints, in order to moot the disclosure claims, avoid nuisance and possible expense and business delays, and provide additional
information to its stockholders, the Company has determined voluntarily to supplement certain disclosures in the Definitive Proxy Statement/Prospectus related to the claims with the supplemental disclosures set forth below (the “Supplemental
Disclosures”). These Supplemental Disclosures should be read in conjunction with the rest of the Definitive Proxy Statement/Prospectus, which is available at the SEC’s website, www.sec.gov and which we urge you to read in its entirety. Nothing in
the Supplemental Disclosures shall be deemed an admission of the legal merit, necessity or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, the Company and its directors and officers specifically deny
all allegations in the Demand Letters and the Complaints, including the allegations that any additional disclosure was or is required or material.
Supplemental Disclosures to the Definitive Proxy Statement/Prospectus
To the extent that the information set forth herein differs from or updates information contained in the Definitive Proxy Statement/Prospectus, the information set
forth herein shall supersede or supplement the information in the Definitive Proxy Statement/Prospectus. The inclusion in this supplement to the Definitive Proxy Statement/Prospectus of certain information should not be regarded as an indication
that any of the Company or its directors, affiliates, officers, or other representatives, or any other recipient of this information, considered, or now considers, it to be material, and such information should not be relied upon as such. All
references to sections and subsections herein are references to the corresponding sections or subsections in the Definitive Proxy Statement/Prospectus, all page references are to pages in the Definitive Proxy Statement/Prospectus, and terms used
herein, unless otherwise defined, have the meanings set forth in the Definitive Proxy Statement/Prospectus. For clarity, new text within restated paragraphs from the Definitive Proxy Statement/Prospectus is highlighted with bold, underlined text, and deleted text within restated paragraphs from the Definitive Proxy Statement/Prospectus is highlighted with strikethrough text.
1. The disclosure under the heading “The Merger - Opinion of Standard BioTools’ Financial Advisor - Summary of Centerview Financial Analysis -
Standard BioTools Liquidation Analysis” is hereby amended by replacing the paragraph under such subheading on page 193 of the Definitive Proxy Statement/Prospectus in its entirety with the following:
Centerview reviewed and considered the Standard BioTools Liquidation Analysis prepared by management of Standard BioTools and
noted that the estimates of future cash distributable to Standard BioTools’ stockholders therein resulted in an aggregate implied equity value for Standard BioTools at the time of such distribution of approximately $468,000,000. Centerview divided
the foregoing equity value by the number of fully diluted outstanding shares of Standard BioTools Common Stock (determined using the treasury stock method), based on approximately 391.5 million basic shares,
32.0 million options, 18.7 million restricted stock units and 11.7 million warrants outstanding, in each case based on information provided by management of Standard BioTools as set forth in the Standard BioTools Internal Data. This
analysis resulted in an implied equity value of Standard BioTools Common Stock of $1.14 per share.
2. The disclosure under the heading “The Merger - Opinion of Standard BioTools’ Financial Advisor - Summary of Centerview Financial Analysis -
Treeline Discounted Cash Flow Analysis” is hereby amended by replacing the second and third paragraphs under such subheading on page 193 of the Definitive Proxy Statement/Prospectus in their entirety with the following:
In performing this analysis, Centerview calculated a range of equity values for shares of Treeline Common Stock by (a)
discounting to present value as of June 30, 2026 using discount rates ranging from 12.0% to 15.0% (reflecting Centerview’s analysis of Treeline’s weighted average cost of capital using the capital asset pricing
model and based on considerations that Centerview deemed relevant in its professional judgment and experience, taking into account certain metrics including levered and unlevered betas for comparable group companies): (i) the
forecasted risk-adjusted, after-tax unlevered free cash flows of Treeline over the period beginning on July 1, 2026 and ending on December 31, 2050, utilized by Centerview based on the Treeline Forecasts and (ii) an implied terminal value of
Treeline, and (b) adding to the foregoing results (i) Treeline’s estimated cash balance as of June 30, 2026 of approximately $510 million, (ii) estimated tax savings from usage of Treeline’s estimated
federal net operating losses and (iii) the estimated net impact on Treeline of future capital raising transactions (net of dilution), as set forth in the Treeline Forecasts.
This analysis resulted in a range of implied equity values of Treeline of $3,040 million to $4,205 million. Centerview divided
the foregoing equity values by the number of fully diluted outstanding shares of Treeline Common Stock of approximately 194.1 million (determined using the treasury stock method), based on information
provided by management of Treeline as set forth in the Treeline Internal Data. This analysis resulted in a range of implied equity values of Treeline Common Stock of $15.88 to $21.89 per share.
3. The disclosure under the heading “The Merger - Opinion of Standard BioTools Special Committee’s Financial Advisor - Discounted Cash Flow
Analysis” is hereby amended by replacing the first paragraph under such subheading on page 198 of the Definitive Proxy Statement/Prospectus in its entirety with the following:
UBS performed a discounted cash flow analysis (“DCF Analysis”) of Treeline on a standalone basis using Treeline Projections. UBS
calculated a range of implied present values, as of June 30, 2026, of the standalone after-tax unlevered free cash flows that Treeline is forecasted to generate from July 1, 2026, through December 31, 2050, as set forth in Treeline Projections,
using discount rates ranging between 15.0% and 17.0%, based on UBS’ estimate of Treeline’s weighted average cost of capital, which is referred to as “WACC.” UBS also calculated estimated terminal values for Treeline by applying perpetuity growth
rates ranging from (30)% to 0%, based on UBS’ professional judgment and experience, to Treeline’s terminal year after-tax unlevered free cash flow. based on the Treeline Projections and as described under “ - Summary of Certain Unaudited Prospective Financial Information - Standard BioTools Management Treeline Projections.” The estimated terminal values were then discounted to present value as of June 30,
2026 using discount rates ranging from 15.0% to 17.0%, based on UBS’ estimate of Treeline’s WACC., as calculated by UBS utilizing the capital asset pricing model. UBS then derived a
reference range of implied equity values for Treeline of $2,595 million to $3,270 million from the implied enterprise value reference range resulting from the sum of such present values, by adding Treeline’s projected cash of approximately $510
million, as of June 30, 2026 and per Standard BioTools’ management, and the Aggregate Treeline Exercise Price of approximately $43 million, per Standard BioTools’ management, to derive a range of implied fully diluted equity values for Treeline of
$2,638 million to $3,313 million. UBS then divided the range of implied fully diluted equity values of Treeline by the number of fully diluted shares outstanding of Treeline Capital Stock of approximately 194.1 million, as provided by Standard
BioTools’ management. This analysis indicated a range of implied values per share of Treeline of $13.59 to $17.07.